Author's response to reviews

Title: Safety and Effectiveness of Adalimumab in a Clinical Setting that Reflects Canadian Standard of Care for the Treatment of Rheumatoid Arthritis (RA): Results from the CanAct Study

Authors:

Boulos Haraoui (bharaoui@videotron.ca)
Alfred Cividino (civi@cogeco.ca)
Jacqueline Stewart (istew1@shaw.ca)
Benoit Guerette (benoit.guerette@abbott.com)
Edward C Keystone (edkeystone@mtsiniel.on.ca)

Version: 3 Date: 16 September 2011

Author's response to reviews: see over
We thank the editor for the helpful comments. Below, please find our response *(italicized)* to the one specific comment:

**Editor’s comments:**

I feel that the quality of the ms has increased, particularly by addressing some issues of non-response. Given the numbers in table 3 there should have been some patients experiencing deterioration of the disease. For the reader, particularly the practising rheumatologist, estimation of the therapeutic auspices becomes possible not until before non-success is reported. Although I had wished to see bars not finishing at 60%, I think the scale should not end at 75% but at 100%, this should be changed before publishing the paper.

*The scale of the graphs depicted in Figures 2A and 2B have been modified and now terminate at 100% per the editor’s suggestion.*